Clinical trials: Psoriatic Arthritis
Psoriasis, Psoriatic Arthritis
Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Psoriatic Arthritis (PsA) is a comorbidity that affects a significant proportion of participants with moderate or severe psoriasis.
- Trial name
- TOGETHER (NCT01316224)
- Where
- 15 sites in Colombia
- Volunteers
- 52 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- ICONIC-PsA 1 (NCT06878404)
- Testing
- Icotrokinra, Active reference comparator
- Where
- 155 sites in United States, Argentina and 14 more
- Volunteers
- 552 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
- Trial name
- AgAIN (NCT04632927)
- Testing
- Secukinumab, Ustekinumab
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had…
- Trial name
- NCT04908189
- Testing
- Deucravacitinib, Apremilast
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 729 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).
- Trial name
- Complete-PsA (NCT01559038)
- Where
- 41 sites in Canada
- Volunteers
- 483 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
- Trial name
- NCT02376790
- Testing
- Etanercept, Methotrexate
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 851 people
- Sponsor
- Amgen
Arthritis, Psoriatic
Single Dose PG102 in Patients With Active Psoriatic Arthritis
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis.
- Trial name
- NCT00787137
- Testing
- PG102
- Where
- Serbia
- Volunteers
- 17 people
- Sponsor
- PanGenetics UK Limited
Juvenile Psoriatic Arthritis
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
- Trial name
- NCT06869551
- Testing
- Deucravacitinib
- Where
- 48 sites in United States, Brazil and 9 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Spondylitis, Ankylosing, Arthritis, Rheumatoid
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
The purpose of this observational study is to evaluate the safety and effectiveness of infliximab injection under actual conditions of use in participants, and to learn more about its adverse events.
- Conditions
- Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic
- Trial name
- NCT00760669
- Testing
- Infliximab; observational study, Methotrexate; observational study
- Volunteers
- 1,061 people
- Sponsor
- Janssen Korea, Ltd., Korea
Arthritis, Psoriatic
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis
- Trial name
- NCT00646386
- Testing
- adalimumab
- Volunteers
- 315 people
- Sponsor
- Abbott
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and…
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03357471
- Testing
- e-Device
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma S.P.R.L.
Arthritis, Rheumatoid, Spondyloarthritis, Axial
Biologic Treatment Registry Across Canada
This registry is a multi-center, prospective, longitudinal, observational program that will gather and analyse data on participants treated with infliximab, golimumab, golimumab Intravenous (I.V) or ustekinumab.
- Conditions
- Arthritis, Rheumatoid, Spondyloarthritis, Axial, Arthritis, Psoriatic
- Trial name
- BioTRAC (NCT00741793)
- Where
- Canada
- Volunteers
- 2,821 people
- Sponsor
- Janssen Inc.
Psoriasis and Psoriatic Arthritis
Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects
An open label, balanced, randomized, two-sequence, two-treatment, two-period, single oral dose, crossover, bioequivalence study in normal, healthy, adult, human subjects under fasting condition
- Trial name
- NCT06084663
- Testing
- Apremilast 30 mg Tablets, Otezla 30 mg film-coated tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Arthritis, Psoriatic
A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment
Observational, prospective and multicenter study in approximately 25 sites nationwide. The investigators participating in this study will be rheumatologists specializing in this pathology.
- Trial name
- PREVAIL (NCT03828045)
- Testing
- Apremilast
- Where
- 20 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Psoriatic Arthritis
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
To demonstrate the relative bioavailability, parallel study Of Leflunomide 20 mg tablets under fasting conditions.
- Trial name
- NCT00946686
- Testing
- Leflunomide 20 mg Tablets (Geneva Pharmaceutical), Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sandoz
Arthritis, Psoriatic
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
- Trial name
- PsABIOnd (NCT05049798)
- Testing
- Guselkumab, IL-17i
- Where
- 155 sites in Argentina, Australia and 18 more
- Volunteers
- 1,314 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Psoriatic Arthritis
The Effect of Psoriatic Arthritis on Female Sexual Dysfunction
Psoriasis is one of the most common immunemediated chronic inflammatory skin disorders.
- Trial name
- NCT06370221
- Testing
- The effect of psoriatic Arthritis
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Psoriatic Arthritis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide…
- Trial name
- TOGETHER-PsA (NCT06588296)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 86 sites in United States, Puerto Rico
- Volunteers
- 279 people
- Sponsor
- Eli Lilly and Company
Autoimmune Diseases
A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis
Chemokine (C-C motif) ligand 20 (CCL20) is a protein involved in attracting immune cells including subsets of T cells (for example Th17 cells), B cells, natural killer cells and dendritic cells to inflamed tissues in conditions…
- Trial name
- NCT02671188
- Testing
- GSK3050002
- Where
- United Kingdom
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals